A UCLA clinical trial found that adding immunotherapy to chemotherapy before surgery is safe for borderline-resectable pancreatic cancer patients, with a subset experiencing deep, durable responses including complete tumor regression.
A UCLA study found that adding immunotherapy to chemotherapy before surgery is safe for borderline-resectable pancreatic cancer patients, with a subset experiencing complete tumor regression despite no overall survival advantage.
Researchers have developed attenuated Listeria bacteria therapies that boost innate immune cells to fight cancer. Two approaches target colorectal cancer and pediatric leukemia, with FDA clearance expected soon for trials in children.
